Docoh
Loading...

38 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Definitive proxy
2:51pm
, warrants or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole
PRE 14A
PCSA Processa Pharmaceuticals Inc
1 Sep 21
Preliminary proxy
4:46pm
or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
, if approved; the rate and degree of market acceptance of our product candidates by physicians, patients, third-party payors and others in the medical community … ; the rate and degree of market acceptance of our product candidates by physicians, patients, third-party payors and others in the medical community
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
by physicians, patients, third-party payors and others in the medical community, if approved; the implementation of our business model, strategic plans
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
with the shared community of legal interests existing between Ocuphire and Processa, including the community of legal interests in avoiding infringement
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities. These and other risks
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
with the Strategic Drug Development Division of ICON, GloboMax, and Mercer Management Consulting. Ms. Guy received an A.A. from Mount Wachusett Community College … the exercise of any stock option, warrants or other rights. Except as otherwise indicated, and subject to applicable community property laws
424B3
PCSA Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
of market acceptance of our product candidates by physicians, patients, third-party payors and others in the medical community, if approved
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
Community College. Patrick Lin – Mr. Lin has served as our Chief Business & Strategy Officer since October 4, 2017, served as a director from … . Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment
S-3
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
candidates by physicians, patients, third-party payors and others in the medical community, if approved; the implementation of our business model
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
of our product candidates by physicians, patients, third-party payors and others in the medical community, if approved; the implementation of our … : The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
will depend upon each product’s acceptance by the medical community (including physicians, patients and health care payors) and the potential competitive … profitability. Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
by the medical community (including physicians, patients and health care payors) and the potential competitive products available to the patients upon … the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
. If approved for marketing, the commercial success of our product candidates will depend upon each product’s acceptance by the medical community (including … not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party
S-1/A
EX-10.13
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
, that they will not be deemed to waive any applicable attorney-client or attorney work product or other privilege and that they are made in connection with the shared community … of legal interests existing between Elion and Processa, including the community of legal interests in avoiding infringement of any valid, enforceable
S-1/A
EX-10.11
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
with the shared community of legal interests existing between Yuhan and Processa, including the community of legal interests in avoiding infringement
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
, that they will not be deemed to waive any applicable attorney-client or attorney work product or other privilege and that they are made in connection with the shared community … of legal interests existing between Elion and Processa, including the community of legal interests in avoiding infringement of any valid, enforceable
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
with the shared community of legal interests existing between Yuhan and Processa, including the community of legal interests in avoiding infringement
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
candidates will depend upon each product’s acceptance by the medical community (including physicians, patients and health care payors) and the potential … not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party payors on the benefits of our product
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
: The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products … by the medical community (including physicians, patients and health care payors) and the potential competitive products available to the patients upon